Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis decreasing the EPHB6 suppressor expression

Early studies suggested that using the recently developed anti-androgen Enzalutamide (Enz, also named as MDV3100) with ADT could extend castration resistant prostate cancer (CRPC) patients' survival extra 4.8 months. Yet the therapy in most patients might eventually fail due to development of Enz-resistance. Here we found Enz might also increase some unwanted side-effects via increasing the CRPC cell invasion that might involve altering the Enz-androgen receptor (AR)/EPHB6 suppressor/JNK signaling.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uQev1L
via IFTTT